Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBITDA (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBITDA for 10 consecutive years, with $301.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 346.69% to $301.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$120.0 million through Dec 2025, up 77.61% year-over-year, with the annual reading at -$120.0 million for FY2025, 77.61% up from the prior year.
  • EBITDA for Q4 2025 was $301.7 million at Ultragenyx Pharmaceutical, up from -$170.9 million in the prior quarter.
  • The five-year high for EBITDA was $301.7 million in Q4 2025, with the low at -$225.1 million in Q3 2022.
  • Average EBITDA over 5 years is -$112.8 million, with a median of -$134.3 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 150.55% in 2022, then skyrocketed 346.69% in 2025.
  • Over 5 years, EBITDA stood at -$102.6 million in 2021, then plummeted by 41.99% to -$145.6 million in 2022, then grew by 16.33% to -$121.8 million in 2023, then decreased by 0.38% to -$122.3 million in 2024, then surged by 346.69% to $301.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $301.7 million, -$170.9 million, and -$107.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.